Disease · MONDO_0005607
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| R500 vs Placebo: serious adverse events | 8 of 79 | 5 of 79 | 158 | NCT01509677 | Trial comparisons |
| Tozorakimab vs Placebo: Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs | 1 of 67 | 0 of 68 | 135 | NCT04631016 | Trial comparisons |
| Tozorakimab vs Placebo: Number of Participants Experiencing First Chronic Obstructive Pulmonary Disease Composite Exacerbations (COPDCompEx) Event | 28 of 67 | 36 of 68 | 135 | NCT04631016 | Trial comparisons |
| Tozorakimab vs Placebo: deaths from any cause | 0 of 67 | 0 of 68 | 135 | NCT04631016 | Trial comparisons |
| Tozorakimab vs Placebo: serious adverse events | 14 of 67 | 9 of 68 | 135 | NCT04631016 | Trial comparisons |
| N-Acetylcysteine vs Placebo: deaths from any cause | 0 of 23 | 0 of 22 | 45 | NCT01739790 | Trial comparisons |
| N-Acetylcysteine vs Placebo: serious adverse events | 3 of 23 | 2 of 22 | 45 | NCT01739790 | Trial comparisons |
| Ivacaftor vs Placebo: Safety of Ivacaftor - Number of Participants With Abnormal Serum Chemistry | 0 of 29 | 0 of 10 | 39 | NCT03085485 | Trial comparisons |
| Ivacaftor vs Placebo: Safety of Ivacaftor - Number of Participants With Abnormal Hematology | 0 of 29 | 0 of 10 | 39 | NCT03085485 | Trial comparisons |
| Ivacaftor vs Placebo: deaths from any cause | 19 of 29 | 6 of 10 | 39 | NCT03085485 | Trial comparisons |
| Ivacaftor vs Placebo: Safety of Ivacaftor - Number of Participants With Abnormal ECG (Prolonged QT Intervals) | 1 of 29 | 1 of 10 | 39 | NCT03085485 | Trial comparisons |
| Ivacaftor vs Placebo: serious adverse events | 6 of 29 | 1 of 10 | 39 | NCT03085485 | Trial comparisons |
| Roflumilast vs Placebo: serious adverse events | 0 of 11 | 0 of 16 | 27 | NCT01572948 | Trial comparisons |
| Prednisone vs Placebo: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT03861390 | Trial comparisons |
| Prednisone vs Placebo: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT03861390 | Trial comparisons |
| Tozorakimab vs Placebo: Number of Participants Seropositive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | 6 of 6 | 6 of 7 | 13 | NCT04631016 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005607/comparisons